EF Hutton Reiterates Buy on Mind Medicine, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Mind Medicine (NASDAQ:MNMD) and maintained a price target of $21.
August 04, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst has reiterated a 'Buy' rating on Mind Medicine and maintained a price target of $21.
The reiteration of a 'Buy' rating and maintenance of a high price target by a reputable analyst like Elemer Piros from EF Hutton is a strong positive signal for Mind Medicine. This could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100